MGC Pharma (ASX:MXC)
- Ticker 2:OTC:MGCLF
- CEO:Roby Zomer
MGC Pharma (ASX:MXC) Stock Price
MGC Pharma (ASX:MXC) Company Overview
MGC Pharmaceuticals (ASX: MXC) is a biotech firm that is currently developing a number of cannabis-based medicinal products such as "CogniCann", which is intended to treat patients suffering from dementia and Alzheimer's.
The company's manufacturing facility in Slovenia recently received one of the European Union's first approvals to extract and develop Phytocannabinoid active pharmaceutical ingredients (API). This will give MGC a considerable competitive advantage as it pursues full vertical integration in the increasingly crowded biopharma market.
MGC Pharmaceuticals was also the first Australian cannabis company to be granted qualification for all of its' Phytomedicines from the European Medicines Agency, allowing it to apply for drug evaluation and registration of CogniCann, CannEpil, and any other medicinal cannabis products currently being developed.
CannEpil is another cannabis-based medicine developed by MGC that is intended to aid the sufferers of epilepsy regulate their symptoms. A growing amount of medical practitioners have already been granted approval to prescribe the drug to Australian patients.
- Address:1202 Hay Street, West Perth, WA 6005, Australia
MGC Pharma (ASX:MXC) Financials
The latest update from the companyClick Here
Stay updated about
Signup to get updates.
Zomer intialy joined MGC Pharmaceuticals as the company’s Executive Director & CTO—bringing his extensive business contacts, scientific and engineering skillset to the role—before being appointed to CEO following the successful implementation of MGC’s pipelines for Pharma in Australia and Slovenia.
He was previously employed as the CEO of a leading cannabis company with a large patient base, before founding MGC Pharmaceuticals with the goal of raising the quality of—and access to—Medicinal Phytocannabinoid products for patients worldwide.
Mitchell has also been involved in the founding, financing and management of private and publicly listed resource companies, and holds both executive and non-executive directorship roles.
For the past 20 years, Walker has been focusing on preventative cardiology, and is considered to be one of Australia’s leading preventative health experts.
He is also the author of seven best-selling books, and a health presenter in the Australian Media, as well as having a weekly radio show on Sydney’s 2UE/ 4BC &2CC.